Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human.

作者信息

Muraki Isao

机构信息

Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University.

出版信息

J Atheroscler Thromb. 2021 Apr 1;28(4):317-318. doi: 10.5551/jat.ED144. Epub 2020 Oct 1.

DOI:10.5551/jat.ED144

PMID:32999210

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8147015/

Abstract

摘要

相似文献

[1]

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human.

J Atheroscler Thromb. 2021-4-1

[2]

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.

Arterioscler Thromb Vasc Biol. 2016-8

[3]

Role of PCSK9 in lipid metabolism and atherosclerosis.

Biomed Pharmacother. 2018-5-11

[4]

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.

Cardiovasc Ther. 2017-11-25

[5]

Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.

J Am Heart Assoc. 2016-6-10

[6]

The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.

Cardiovasc Ther. 2017-11-23

[7]

Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Cardiovasc Res. 2016-10

[8]

[PCSK9 inhibitors : New treatment option in clinical practice].

Herz. 2016-6

[9]

Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.

Pharmacol Ther. 2016-4-29

[10]

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.

Eur Heart J. 2015-11-17

引用本文的文献

[1]

Regulatory mechanisms of hepatocyte PCSK9 expression: translating mechanistic insights into potential nutraceuticals.

Chin Med. 2025-8-5

[2]

Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis.

Iran J Public Health. 2023-5

本文引用的文献

[1]

Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.

J Atheroscler Thromb. 2021-4-1

[2]

Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis.

Curr Atheroscler Rep. 2020-6-16

[3]

Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.

Circulation. 2020-1-29

[4]

Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.

Clin Biochem. 2020-1-20

[5]

Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils Lowers Atherogenic Lipoprotein Classes Without Increasing Lipoprotein(a).

J Nutr. 2020-4-1

[6]

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

J Atheroscler Thromb. 2018-9-1

[7]

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.

Circulation. 2016-2-19

[8]

Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study.

J Atheroscler Thromb. 2014

[9]

Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment.

Crit Rev Toxicol. 2006-2

[10]

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Nat Genet. 2003-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献